Synthesis of 9-[1-(substituted)-3-(phosphonomethoxy)propyl]adenine derivatives as possible antiviral agents

Nucleosides, Nucleotides and Nucleic Acids

Volumn 24, Issue 10-12, 2005, Pages 1543-1568

  Wu, Minwan ^a   El Kattan, Yahya ^a   Lin, Tsu Hsing ^a   Ghosh, Ajit ^a   Vadlakonda, Satish ^a   Kotian, Pravin L ^a   Babu, Yarlagadda S ^a   Chand, Pooran ^a,b  

^a BioCryst Pharmaceuticals   (United States)

^b BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

Acyclic nucleosides; Antiviral; Prodrugs

Indexed keywords

1 TERT BUTYLDIMETHYLSILYL 4 PIVALOYLBUTAN 1,2,4 TRIOL; 9 [1 AMINOMETHYL [3 (DIISOPROPYLPHOSPHONO)METHOXY]PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 AZIDOMETHYL (3 PHOSPHONOMETHOXY)PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 AZIDOMETHYL [3 (DI TERT BUTYLCARBONYLOXYMETHYLPHOSPHONO)METHOXY] PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 AZIDOMETHYL [3 (DIISOPROPYLPHOSPHONO)METHOXY]PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 FLUOROMETHYL [3 (DIISOPROPYLPHOSPHONO)METHOXY]PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 HYDROXYMETHYL [3 (DIISOPROPYLPHOSPHONO)METHOXY]PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 METHOXYMETHYL (3 PHOSPHONOMETHOXY)PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 METHOXYMETHYL [3 (DI TERT BUTYLCARBONYLOXYMETHYLPHOSPHONO)METHOXY] PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 METHOXYTRITYLAMINOMETHYL [3 (DIISOPROPYLPHOSPHONO)METHOXY]PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 METHOXYTRITYLOXYMETHYL (3 PHOSPHONOMETHOXY)PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 METHOXYTRITYLOXYMETHYL [3 (DI TERT BUTYLCARBONYLOXYMETHYLPHOSPHONO) METHOXY]PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 METHOXYTRITYLOXYMETHYL [3 (DIISOPROPYLPHOSPHONO)METHOXY]PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 METHYL (3 PHOSPHONOMETHOXY)PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 METHYL [3 (DI TERT BUTYLCARBONYLOXYMETHYLPHOSPHONO)METHOXY]PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 METHYLENE (3 PHOSPHONOMETHOXY)PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 METHYLENE [3 (DIISOPROPYLPHOSPHONO)METHOXY]PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 N METHOXYTRITYLAMINOMETHYL (3 PHOSPHONOMETHOXY)PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 N METHOXYTRITYLAMINOMETHYL [3 (DI TERT BUTYLCARBONYLOXYMETHYLPHOSPHONO)METHOXY]PROPYL] N6 METHOXYTRITYLADENINE; 9 [1 TOSYLOXYMETHYL [3 (DIISOPROPYLPHOSPHONO)METHOXY]PROPYL] N6 METHOXYTRITYLADENINE; 9 [[1 (ALPHA METHOXYTRITYLOXY)ETHYL][3 (DI TERT BUTYLCARBONYLOXYMETHYLPHOSPHONO)METHOXY]PROPYL] N6 METHOXYTRITYLADENINE; ADENINE; ADENINE DERIVATIVE; ANTIVIRUS AGENT; BUTANE; HYDROXYL GROUP; PHOSPHORUS DERIVATIVE; PRODRUG; SILICON DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ARTICLE; CHEMICAL MODIFICATION; DRUG SYNTHESIS; MITSUNOBU REACTION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HEPATITIS C VIRUS; HUMAN; SYNTHESIS; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; HEPACIVIRUS; HUMANS; PHOSPHONIC ACIDS; PRODRUGS; VIRUS REPLICATION;

EID: 29244458686     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770500268673     Document Type: Article

References (37)

1. Consensus Panel. EASL International Consensus Conference on Hepatitis C, Paris, 26-28 February 1999, Consensus Statement. J. Hepatol. 1999, 30, 956.
2. (a) Cohen, J. The scientific challenge of hepatitis C. Science 1999, 285, 26;
3. (b) Houghten, M. In Virology; Fields, B.N., Knipe, D.M., Howley, P.M., Eds.; Raven: New York, 1996; 1035-1058;
4. (c) Cuthbert, J.A. Hepatitis C: Progress and problems. Clin. Microbiol. Rev. 1994, 7(4), 505-532.
5. Dymock, B.W. Emerging therapies for hepatitis C infection. Emerging Drugs 2001, 6(1), 13-42, and references cited therein.
6. (a) Schaeffer, H.J.; Beauchamp, L.; de Miranda, P.; Elion, G.B.; Bauer, D.J.; Collins, P. 9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group. Nature (London) 1978, 272(5654), 583-585;
7. (b) Elion, G.B.; Furman, P.A.; Fyfe, J.A.; de Miranda, P.; Beauchamp, L.; Schaeffer, H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc. Natl. Acad. Sci. U.S.A. 1977, 74(12), 5716-5720;
8. (c) Collins, P.; Bauer, D.J. The activity in vitro against herpes virus of 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine), a new antiviral agent. J. Antimicrob. Chemother. 1979, 5(4), 431-436.
9. (a) Smith, K.O.; Galloway, K.S.; Kennell, W.L.; Ogilvie, K.K.; Radatus, B.K. A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl] guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob. Agents Chemother. 1982, 22(1), 55-61;
10. (b) Ashton, W.T.; Karkas, J.D.; Field, A.K.; Tolman, R.L. Activation by thymidine kinase and potent antiherpetic activity of 2′-nor-2′- deoxyguanosine (2′NDG). Biochem. Biophys. Res. Commun. 1982, 108(4), 1716-1721;
11. (c) Martin, J.C.; Dvorak, C.A.; Smee, D.F.; Matthews, T.R.; Verheyden, J.P.H. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: A new potent and selective antiherpes agent. J. Med. Chem. 1983, 26(5), 759-761;
12. (d) Schaeffer, H.J. In Nucleosides, Nucleotides and their Biological Applications; Rideout, J.L., Henry, D.W., Beacham, L.M., Eds.; Academic Press: New York, 1983; 1-17.
13. (a) Cheng, Y.-C.; Huang, E.-S.; Lin, J.-C.; Mar, E.-C.; Pagano, J.S.; Dutschman, G.E.; Grill, S.P. Unique spectrum of activity of 9-[(1,3-dihydroxy-2- propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1983, 80(9), 2767-2770;
14. (b) Field, A.K.; Davies, M.E.; Dewitt, C.; Perry, H.C.; Liou, R.; Germershausen, J.; Karkas, J.D.; Ashton, W.T.; Johnston, D.B.; Tolman, R.L. 9-([2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl) guanine: A selective inhibitor of herpes group virus replication. Proc. Natl. Acad. Sci. U.S.A. 1983, 80(13), 4139-4143.
15. Smee, D.F.; Martin, J.C.; Verheyden, J.P.H.; Matthews, T.R. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2- propoxymethyl)guanine. Antimicrob. Agents Chemother. 1983, 23(5), 676-682.
16. Cundy, K.C. Clinical pharmacokinetics of the antiviral nucleotide analogues Cidofovir and Adefovir. Clin. Pharmacokinet. 1999, 36, 127-143.
17. Holy, A. Phosphonylmethyl analogs of nucleotides and their derivatives: Chemistry and biology. Nucleosides Nucleotides 1987, 6(1&2), 147-155.
18. Kim, C.U.; Luh, B.Y.; Misco, P.F.; Bronson, J.J.; Hitchcock, M.J.M.; Ghazzouli, I.; Martin, J.C. Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships. J. Med. Chem. 1990, 33, 1207-1213.
19. Holy, A.; Dvorakova, H.; Jindrich, J.; Masojidkova, M.; Budesinsky, M.; Balzarini, J.; Andrei, G.; De Clercq, E. Acyclic nucleotide analogs derived from 8-azapurines: Synthesis and antiviral activity. J. Med. Chem. 1996, 39, 4073-4088.
20. Balzarini, J.; Pannecouque, C.; De Clercq, E.; Aquaro, S.; Perno, C.-F.; Egberink, H.; Holy, A. Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates. Antimicrob. Agents Chemother. 2002, 46, 2185-2193.
21. Balzarini, J.; Perno, C.F.; Schols, D.; De Clercq, E. Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 1991, 178, 329-335.
22. De Clercq, E.; Holy, A.; Rosenberg, I.; Sakuma, T.; Balzarini, J.; Maudgal, P.C. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986, 323, 464-467.
23. Naesens, L.; De Clercq, E. Therapeutic potential of HPMPC (Cidofovir), PMEA (Adefovir) and related acyclic nucleoside phosphonate analogues as broad-spectrum antiviral agents. Nucleosides Nucleotides 1997, 16, 983-992.
24. Balzarini, J.; Holy, A.; Jindrich, J.; Naesens, L.; Snoeck, R.; Schols, D.; De Clercq, E. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2- phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 1993, 37, 332-338.
25. Balzarini, J.; Aquaro, S.; Perno, C.-F.; Holy, A.; De Clercq, E. Activity of the (R)-enantiomers of 9-(2-phosphonyl-methoxypropyl)adenine and 9-(2-phosphonyl-methoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem. Biophys. Res. Commun. 1996, 219, 337-341.
26. Holy, A.; Gunter, J.; Dvorakova, H.; Masojidkova, M.; Andrei, G.; Snoeck, R.; Balzarini, J.; De Clercq, E. Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy) ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base. J. Med. Chem. 1999, 42, 2064-2086.
27. Kamiya, N.; Kubota, A.; Iwase, Y.; Sekiya, K.; Ubasawa, M.; Yuasa, S. Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 2002, 46, 2872-2877.
28. Perbost, M.; Lucas, M.; Chavis, C.; Imbach, J.-L. Synthesis of racemic carboacyclonucleosides derived from butane-1,4-diol and hexane-1,6-diol. Nucleosides Nucleotides 1992, 11(8), 1489-1505.
29. Perbost, M.; Lucas, M.; Chavis, C.; Imbach, J.-L. An expeditious synthesis of homochiral (R) 2-(9-purinyl)butane-1,4-diols from (S) butane-1,2,4-triol. Nucleosides Nucleotides 1992, 11(8), 1529-1537.
30. Jeffery, A.L.; Kim, J.-H.; Wiemer, D.F. Synthesis of acyclic nucleoside and nucleotide analogues from amino acids: A convenient approach to a PMEA-PMPA hybrid. Tetrahedron 2000, 56, 5077-5083.
31. Giller, S.A.; Getsova, I.N.; Goncharova, I.N.; Petrulyanis, L.N.; Mironova, L.I.; Nazarova, G.F.; Bruk, E.I. Analogs of purine nucleosides and purine mono- and polynucleotides. II. Substituted α-(9-purinyl)-γ- butyrolactones. Chem. Heterocycl. Compd. U.S.S.R. 1974, 10, 1477-1480.
32. Hanessian, S.; Ugolini, A.; Dube, D.; Glamyan, A. Facile access to (S)-1,2,4-butanetriol and its derivatives. Can. J. Chem. 1984, 62, 2146-2147.
33. Koert, U.; Wagner, H.; Pidun, U. Stereoselective additions of chiral, functionalized organozinc reagents to achiral and chiral aldehydes: Matched-mismatched case in organozinc chemistry. Chem. Ber. 1994, 127(8), 1447-1457.
34. Hossain, N.; Rozenski, J.; De Clercq, E.; Herdewijn, P. Synthesis and antiviral activity of acyclic analogues of 1,5-anhydrohexitol nucleosides using mitsunobu reaction. Tetrahedron 1996, 52(43), 13655-13670.
35. Townsend, L.B.; Robins, R.K.; Loeppky, R.N.; Leonard, N.J. Purine nucleosides. VIII. Reinvestigation of the position of glycosidation in certain synthetic "7"-substituted 6-dimethylaminopurine nucleosides related to puromycin. J. Am. Chem. Soc. 1964, 86, 5320-5325.
36. Goergens, U.; Schneider, M.P. Enzymatic preparation of enantiomerically pure and selectively protected 1,2- and 1,3-diols. J. Chem. Soc. Chem. Commun. 1991, 16, 1066-1068.
37. Carroll, S.S.; Tomassini, J.E.; Bosserman, M.; Getty, K.; Stahlhut, M.W.; Eldrup, A.B.; Bhat, B.; Hall, D.; Simcoe, A.L.; LaFemina, R.; Rutkowski, C.A.; Wolanski, B.; Yang, Z.; Migliaccio, G.; De Francesco, R.; Kuo, L.C.; MacCoss, M.; Olsen, D.B. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 2003, 278, 11979-11984.